Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Larry Moreland to Antibodies, Monoclonal

This is a "connection" page, showing publications Larry Moreland has written about Antibodies, Monoclonal.

 
Connection Strength
  
 
 
2.338
  
  1. Hwang YG, Moreland LW. Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. Curr Rheumatol Rep. 2014 May; 16(5):417.
    View in: PubMed
    Score: 0.256
  2. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther. 2010 Oct 01; 4:263-78.
    View in: PubMed
    Score: 0.199
  3. Moreland L. Adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2004 Oct; 6(5):333-4.
    View in: PubMed
    Score: 0.132
  4. Moreland L. Infliximab in rheumatoid arthritis. Curr Rheumatol Rep. 2004 Oct; 6(5):334-5.
    View in: PubMed
    Score: 0.132
  5. Mikuls TR, Moreland LW. Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf. 2003; 26(1):23-32.
    View in: PubMed
    Score: 0.117
  6. Daniel CL, Moreland LW. Infliximab: additional safety data from an open label study. J Rheumatol. 2002 Apr; 29(4):647-9.
    View in: PubMed
    Score: 0.111
  7. Moreland LW. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. Isr Med Assoc J. 2001 Sep; 3(9):686-90.
    View in: PubMed
    Score: 0.106
  8. Moreland LW, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. J Rheumatol. 2001 Jun; 28(6):1431-52.
    View in: PubMed
    Score: 0.104
  9. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001 Jan; 2(1):75-84.
    View in: PubMed
    Score: 0.101
  10. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
    View in: PubMed
    Score: 0.090
  11. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48(3):1-4.
    View in: PubMed
    Score: 0.088
  12. Moreland LW, Haverty TP, Wacholtz MC, Knowles RW, Bucy RP, Heck LW, Koopman WJ. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis. J Rheumatol. 1998 Feb; 25(2):221-8.
    View in: PubMed
    Score: 0.083
  13. Moreland LW, Heck LW, Koopman WJ. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997 Mar; 40(3):397-409.
    View in: PubMed
    Score: 0.078
  14. Moreland LW. Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis. J Rheumatol Suppl. 1996 Mar; 44:78-83.
    View in: PubMed
    Score: 0.073
  15. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 1995 Nov; 38(11):1581-8.
    View in: PubMed
    Score: 0.071
  16. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum. 1994 Jun; 37(6):834-8.
    View in: PubMed
    Score: 0.064
  17. Moreland LW, Bucy RP, Tilden A, Pratt PW, LoBuglio AF, Khazaeli M, Everson MP, Daddona P, Ghrayeb J, Kilgarriff C, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum. 1993 Mar; 36(3):307-18.
    View in: PubMed
    Score: 0.059
  18. Moreland LW, Pratt PW, Sanders ME, Koopman WJ. Experience with a chimeric monoclonal anti-CD4 antibody in the treatment of refractory rheumatoid arthritis. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S153-9.
    View in: PubMed
    Score: 0.059
  19. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedrén S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010 Jul; 62(7):1849-61.
    View in: PubMed
    Score: 0.049
  20. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 Aug; 60(8):2272-83.
    View in: PubMed
    Score: 0.046
  21. Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf. 2006 Jan; 15(1):11-8.
    View in: PubMed
    Score: 0.036
  22. Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G, Kremer JM. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin. 2005 Aug; 21(8):1181-90.
    View in: PubMed
    Score: 0.035
  23. Robinson WH, Fiorentino D, Chung L, Moreland LW, Deodhar M, Harler MB, Saulsbery C, Kunder R. Cutting-edge approaches to B-cell depletion in autoimmune diseases. Front Immunol. 2024; 15:1454747.
    View in: PubMed
    Score: 0.033
  24. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003 Jun; 25(6):1700-21.
    View in: PubMed
    Score: 0.030
  25. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan; 48(1):35-45.
    View in: PubMed
    Score: 0.029
  26. Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
    View in: PubMed
    Score: 0.028
  27. Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. BioDrugs. 2001; 15(6):379-93.
    View in: PubMed
    Score: 0.025
  28. Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun; 66(6):367-74.
    View in: PubMed
    Score: 0.023
  29. Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Louis Bridges S, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 08 23; 7:12460.
    View in: PubMed
    Score: 0.019
  30. Moreland LW, Bucy RP, Koopman WJ. Regeneration of T cells after chemotherapy. N Engl J Med. 1995 Jun 15; 332(24):1651-2.
    View in: PubMed
    Score: 0.017
  31. Moreland LW, Heck LW, Sullivan W, Pratt PW, Koopman WJ. New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. Am J Med Sci. 1993 Jan; 305(1):40-51.
    View in: PubMed
    Score: 0.015
  32. Moreland LW, Stewart T, Gay RE, Huang GQ, McGee N, Gay S. Immunohistologic demonstration of type II collagen in synovial fluid phagocytes of osteoarthritis and rheumatoid arthritis patients. Arthritis Rheum. 1989 Nov; 32(11):1458-64.
    View in: PubMed
    Score: 0.012
  33. Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, Gnann JW, Bloch KC. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
    View in: PubMed
    Score: 0.012
  34. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003 May; 15(3):226-36.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)